Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Statistics & Valuation Metrics

Structure Therapeutics, Inc. Sponsored ADR has a market cap or net worth of $1.56B. The enterprise value is $2.56B.

Market Cap

$1.56B

Enterprise Value

$2.56B

Structure Therapeutics, Inc. Sponsored ADR has 71,309,860 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

71,309,860

Owned by Insiders

10.21%

Owned by Institutions

25.61%

Structure Therapeutics, Inc. Sponsored ADR’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is -18.88%.

Return on Equity (ROE)

-0.09

Return on Assets (ROA)

-0.09

Return on Invested Capital (ROIC)

-18.88%

Return on Capital Employed (ROCE)

-0.19

Revenue Per Employee

0

Profits Per Employee

-502.50K

Employee Count

281

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Structure Therapeutics, Inc. Sponsored ADR is -6.76. Structure Therapeutics, Inc. Sponsored ADR’s PEG ratio is 0.48.

PE Ratio

-6.76

PS Ratio

0.00

PB Ratio

1.10

Price to FCF

-5.25

Price to Operating Cash Flow

-6.75

PEG Ratio

0.48

In the last 12 months, Structure Therapeutics, Inc. Sponsored ADR had revenue of 0 and earned -141.20M in profits. Earnings per share was -2.40.

Revenue

0

Gross Profit

-3.90M

Operating Income

-287.57M

Pretax Income

-140.69M

Net Income

-141.20M

EBITDA

-139.35M

Earnings Per Share (EPS)

-2.40

In the last 12 months, operating cash flow was -220.25M and capital expenditures -4.21M, giving a free cash flow of -224.46M billion.

Operating Cash Flow

-220.25M

Free Cash Flow

-224.46M

Free Cash Flow per Share

-3.09

Structure Therapeutics, Inc. Sponsored ADR pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-19.02%

Earnings Yield

-14.44%

Beta

1.00

52-Week Price Change

-38.57%

50-Day Moving Average

33.40

200-Day Moving Average

48.39

Relative Strength Index (RSI)

26.52

Average Volume (3m)

1.08M

Structure Therapeutics, Inc. Sponsored ADR upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 06, 2026

Next Earnings Date

Nov 18, 2026

Ex-Dividend Date

―

Structure Therapeutics, Inc. Sponsored ADR as a current ratio of 24.81, with Debt / Equity ratio of 0.43%

Current Ratio

24.81

Quick Ratio

24.81

Debt to Market Cap

0.00

Net Debt to EBITDA

5.69

Interest Coverage Ratio

0.00

In the past 12 months, Structure Therapeutics, Inc. Sponsored ADR has paid 515.00K in taxes.

Income Tax

515.00K

Effective Tax Rate

-0.00

Structure Therapeutics, Inc. Sponsored ADR EV to EBITDA ratio is -4.30, with an EV/FCF ratio of -4.07.

EV to Sales

0.00

EV to EBITDA

-4.30

EV to Free Cash Flow

-4.07

EV to Operating Cash Flow

-4.15

Structure Therapeutics, Inc. Sponsored ADR has $1.34B in cash and marketable securities with $6.23M in debt, giving a net cash position of $1.34B billion.

Cash & Marketable Securities

$1.34B

Total Debt

$6.23M

Net Cash

$1.34B

Net Cash Per Share

$18.74

Tangible Book Value Per Share

$18.64

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Structure Therapeutics, Inc. Sponsored ADR is $108.46, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$108.46

Price Target Upside

429.86% Upside

Analyst Consensus

Strong Buy

Analyst Count

14

Revenue Growth Forecast

―

EPS Growth Forecast

1.47%

Smart Score

6

AI Score

52